Pfizer (NYSE:PFE) admitted this morning that it has approached AstraZeneca (NYSE:AZN) twice seeking an opportunity to buy the company, most recently last weekend. In a conference call with analysts on Monday, Pfizer's management laid out the case for why AstraZeneca would be an excellent acquisition for Pfizer -- particularly given that Pfizer has reorganized into three business segments in preparation for a possible breakup in 2017.

In this video from Monday's Market Checkup, Motley Fool health care analysts Michael Douglass and David Williamson lay out the benefits of the acquisition point-by-point, laying out for investors the three reasons Pfizer wants AstraZeneca.

Top dividend stocks for the next decade -- are Pfizer and AstraZeneca on the list?
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

David Williamson owns shares of Pfizer. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.